ID   BB30-HNC
AC   CVCL_1076
SY   BB30 HNC; BB30HNC; BB30-SCCHN
DR   CLO; CLO_0009939
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 832
DR   cancercelllines; CVCL_1076
DR   Cell_Model_Passport; SIDM00172
DR   ChEMBL-Cells; CHEMBL3308548
DR   ChEMBL-Targets; CHEMBL2366271
DR   Cosmic; 753531
DR   Cosmic; 1995343
DR   Cosmic-CLP; 753531
DR   DepMap; ACH-002212
DR   EGA; EGAS00001000978
DR   GDSC; 753531
DR   GEO; GSM1669607
DR   IARC_TP53; 21186
DR   LINCS_LDP; LCL-1573
DR   PharmacoDB; BB30HNC_74_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1076
DR   Wikidata; Q54795061
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser144Ter (c.431C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.96+2T>G (IVS3+2T>G); Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.71%; Native American=0%; East Asian, North=0.53%; East Asian, South=0%; South Asian=0.89%; European, North=70.27%; European, South=27.6% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,14
ST   D5S818: 11
ST   D7S820: 8
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C34447; Head and neck squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VU86 ! BB30-PBL
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//